In this third post on the forthcoming HIPAA/HITECH regulations, we will discuss potential modifications to the rules regarding authorization for future research.  In earlier posts, we covered the Department of Health and Human Service’s (HHS) proposed treatment of communications about currently prescribed drugs and remunerated treatment communications

Future Research

In the proposed rule issued last July, HHS stated that it is “considering whether to modify its interpretation that an authorization for the use or disclosure of protected health information for research be research-study specific.”  The agency was prompted to revisit this issue after hearing concerns from covered entities and researchers about how the current interpretation encumbers secondary research, results in individuals being re-contacted to sign multiple authorization forms at different points in the future, and is inconsistent with the Common Rule.

HHS stated that it is considering a number of options in this area, but requested comments on three options in particular:

  • Option #1.  Amend the HIPAA Privacy Rule to permit an authorization for uses and disclosures for future research purposes to the extent there is an adequate description of such purposes.
  • Option #2.  Amend the HIPAA Privacy Rule to permit an authorization for uses and disclosures for future research purposes to the extent the description of the future research includes specific elements or statements specified by the Privacy Rule.
  • Option #3.  Amend the HIPAA Privacy Rule to permit the first option as the general rule, but require certain disclosure statements in cases where the future research may involve certain types of sensitive research activities (e.g., genetic analyses, mental health research).

HHS’s final determination on this issue could have a significant impact on the conduct of clinical trials and, as science evolves,  the ability of researchers to use data for research purposes that could not have been contemplated at the time the data was gathered, but which hold great promise to expand the base of general knowledge.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Anna D. Kraus Anna D. Kraus

Anna Durand Kraus has a multi-disciplinary practice advising clients on issues relating to the complex array of laws governing the health care industry. Her background as Deputy General Counsel to the U.S. Department of Health and Human Services (HHS) gives her broad experience…

Anna Durand Kraus has a multi-disciplinary practice advising clients on issues relating to the complex array of laws governing the health care industry. Her background as Deputy General Counsel to the U.S. Department of Health and Human Services (HHS) gives her broad experience with, and valuable insight into, the programs and issues within the purview of HHS, including Medicare, Medicaid, fraud and abuse, and health information privacy. Ms. Kraus regularly advises clients on Medicare reimbursement matters, the Medicaid Drug Rebate program, health information privacy issues (including under HIPAA and the HITECH Act), and the challenges and opportunities presented by the Affordable Care Act.